Johnson & Johnson announced that the U.S. FDA has approved the supplemental Biologics License Application for TECVAYLI for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for a minimum of six months. There is a continued unmet need for patients with multiple myeloma and this approval allows increased flexibility in dosing schedule for appropriate patients with a weight-based regimen.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- BTIG medical technology analyst to hold analyst/industry conference call
- Unusually active option classes on open February 15th
- Johnson & Johnson (NYSE:JNJ) Slips despite New Frostbite Treatment
- MeiraGTx announces $50M milestone from Janssen Pharmaceuticals
- J&J lawsuit may spur adoption of GoodRx program, says Citi
